IL6 and congenital rubella syndrome: Current data support a key role of IL-6 release in the pathogenesis of CRS, based on correlation of markedly elevated IL-6 levels with signs and symptoms of CRS (13, 64), as well as observational evidence of rapid resolution of CRS after administration of the IL-6 receptor blocker tocilizumab (95).